2026-04-17T06:05:17Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1573072025-12-05T13:17:22Zcom_2072_1057col_2072_478798col_2072_478858col_2072_478916col_2072_478917col_2072_478921

14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis Martínez Yélamos, Antonio Saiz Hinarejos, Albert Sánchez del Valle Díaz, Raquel Casado Ruiz, Virginia Ramon Torrell, Josep M. (Josep Maria) Graus Ribas, Francesc Arbizu Urdiain, Txomin Líquid cefalorraquidi Esclerosi múltiple Proteïna-tirosina-fosfatasa Cerebrospinal fluid Multiple sclerosis Protein-tyrosine phosphatase Axonal damage probably occurs early in the evolution of MS. Five of 38 (13%) patients had a positive assay for the neuronal 14-3-3 protein in the CSF obtained at the first clinically isolated syndrome suggestive of MS. A positive 14-3-3 assay was the only independent predictor for a shorter time to conversion to clinical definite MS (risk ratio 4.1; 95% CI 1.1 to 15) and to reach an Expanded Disability Status Scale (EDSS) > or =2 at the end of follow-up (odds ratio 14.8; 95% CI 2.86 to 76.8). The detection of the 14-3-3 protein in the CSF at the first neurologic event suggestive of MS may be a useful predictor of short-term evolution. 2020-04-24T11:17:43Z 2020-04-24T11:17:43Z 2001-08-28 2020-04-24T11:17:43Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1212/wnl.57.4.722 Neurology, 2001, vol. 57, num. 4, p. 722-724 https://doi.org/10.1212/wnl.57.4.722 (c) American Academy of Neurology, 2001 info:eu-repo/semantics/openAccess Lippincott, Williams & Wilkins. Wolters Kluwer Health Articles publicats en revistes (Ciències Clíniques)